Literature DB >> 15238797

Venom immunotherapy: adverse reactions and treatment failure.

Franziska Ruëff1, Bernhard Przybilla.   

Abstract

PURPOSE OF REVIEW: Side effects of venom immunotherapy and lack of efficacy represent significant problems in the treatment of patients allergic to Hymenoptera venom. Among these side effects systemic anaphylactic reactions and large local reactions are the most important. This review aims to discuss new insights in frequency, pathogenesis and handling of these common side effects and of treatment failure during venom immunotherapy. RECENT
FINDINGS: Several studies showed that severe side effects due to venom immunotherapy are rare. Recently published studies focus on ultrarush protocols and report good tolerance of an ultrarush venom immunotherapy in which the maintenance dose was reached within several hours or 2 days, respectively. Compared to the use of aqueous extracts (administered according to a rush protocol), frequency of local and also systemic side effects was lower when depot extracts and schedules with a slow conventional dose increase were applied. Concomitant treatment with H1-antihistamines was found to reduce local and mild systemic adverse reactions during venom immunotherapy. Up to 25% of patients are not protected when re-stung while on venom immunotherapy with the usual maintenance dose of 100 microg of venom every 4-8 weeks. These patients can achieve full protection by increasing the maintenance dose.
SUMMARY: Conventional dose increase using depot extracts is better tolerated than if aqueous extracts are being administered. Concomitant treatment with H1-antihistamines may be helpful. Increasing the venom dose to 200 microg or even more may be therapeutically effective in patients not protected by a lower maintenance dose. To compare tolerance of different treatment protocols prospective comparative studies are required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238797     DOI: 10.1097/01.all.0000136754.13077.fc

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  8 in total

1.  Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998.

Authors:  Rolf Haye; Liv Kari Døsen
Journal:  Clin Mol Allergy       Date:  2005-08-19

2.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors:  D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

Review 3.  Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.

Authors:  Zsolt Szépfalusi; Saskia Gruber; Thomas Eiwegger; Eleonora Dehlink
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

Review 4.  Anaphylaxis to insect venom allergens: role of molecular diagnostics.

Authors:  Markus Ollert; Simon Blank
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

5.  Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit.

Authors:  Ewa Cichocka-Jarosz; Marcin Stobiecki; Marita Nittner-Marszalska; Urszula Jedynak-Wąsowicz; Piotr Brzyski
Journal:  Postepy Dermatol Alergol       Date:  2019-06-19       Impact factor: 1.837

Review 6.  Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management.

Authors:  Troy Wanandy; Emily Mulcahy; Wun Yee Lau; Simon G A Brown; Michael D Wiese
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-01       Impact factor: 8.667

Review 7.  Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.

Authors:  Simon Blank; Johannes Grosch; Markus Ollert; Maria Beatrice Bilò
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

Review 8.  Venom Immunotherapy: From Proteins to Product to Patient Protection.

Authors:  Martin Feindor; Matthew D Heath; Simon J Hewings; Thalia L Carreno Velazquez; Simon Blank; Johannes Grosch; Thilo Jakob; Peter Schmid-Grendelmeier; Ludger Klimek; David B K Golden; Murray A Skinner; Matthias F Kramer
Journal:  Toxins (Basel)       Date:  2021-09-01       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.